Form 4: Karyopharm Therapeutics CEO Sells Shares to Cover Tax Obligations
SEC Form 4
Richard A. Paulson, CEO of Karyopharm Therapeutics, sold 3,607 shares of common stock to cover withholding tax liabilities.
Summary
- Richard A. Paulson, the President and CEO of Karyopharm Therapeutics Inc., sold 3,607 shares of common stock on October 4, 2024.
- The shares were sold at a price of $0.8793 per share.
- The sale was executed to cover withholding tax liabilities incurred upon the vesting of restricted stock units.
- Following the transaction, Paulson directly owns 1,135,607 shares of Karyopharm Therapeutics Inc.
Sentiment
Score: 5
Explanation: The document describes a routine stock sale to cover tax obligations, which is neither particularly positive nor negative.
Industry Context
Sales of shares to cover tax obligations are a routine part of executive compensation and are not necessarily indicative of the executive's sentiment about the company's future prospects.
Key Dates
| Date | Description |
|---|---|
| June 10, 2021 | Date the reporting person adopted a durable automatic sale instruction plan. |
| 10/04/2024 | Date of the transaction (stock sale). |
| 10/07/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.